Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BCTX BriaCell Therapeutics

6.120
+0.200+3.38%
Close 10/05 16:00 ET
5.870
-0.250-4.08%
Pre Mkt Price 10/06 07:24 ET
High
6.230
Open
6.040
Turnover
2.31M
Low
5.830
Pre Close
5.920
Volume
381.41K
Market Cap
94.86M
P/E(TTM)
Loss
52wk High
12.470
Shares
15.50M
P/E(Static)
Loss
52wk Low
4.060
Float Cap
72.56M
Bid/Ask %
-60.00%
Historical High
12.470
Shs Float
11.86M
Volume Ratio
1.41
Historical Low
2.815
Dividend TTM
--
Div Yield TTM
--
P/B
2.07
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.22%
Amplitude
6.76%
Avg Price
6.057
Lot Size
1
Float Cap
72.56M
Bid/Ask %
-60.00%
Historical High
12.470
Shs Float
11.86M
Volume Ratio
1.41
Historical Low
2.815
Dividend TTM
--
P/B
2.07
Dividend LFY
--
Turnover Ratio
3.22%
Amplitude
6.76%
Avg Price
6.057
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
CEO: Dr. William Williams, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...